Deutsch
 
Hilfe Datenschutzhinweis Impressum
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT
  Cancer-Associated Fibroblasts in Inflammation and Antitumor Immunity

Kennel, K. B., Bozlar, M., De Valk, A. F., & Greten, F. R. (2023). Cancer-Associated Fibroblasts in Inflammation and Antitumor Immunity. CLINICAL CANCER RESEARCH, 29(6), 1009-1016. doi:10.1158/1078-0432.CCR-22-1031.

Item is

Basisdaten

einblenden: ausblenden:
Genre: Zeitschriftenartikel

Externe Referenzen

einblenden:

Urheber

einblenden:
ausblenden:
 Urheber:
Kennel, Kilian B., Autor
Bozlar, Muege1, Autor           
De Valk, Adalbert F., Autor
Greten, Florian R., Autor
Affiliations:
1IMPRS, Max Planck Institute for Heart and Lung Research, Max Planck Society, ou_3242057              

Inhalt

einblenden:
ausblenden:
Schlagwörter: -
 Zusammenfassung: Tumor-associated inflammation (TAI) is a feature of essen-tially all cancers and can confer both tumor-promoting and-suppressive functions. Cancer-associated fibroblasts (CAF) comprise one very heterogeneous cellular component of the tumor microenvironment characterized by a high degree of plasticity. Recent single-cell sequencing analyses revealed dis-tinct CAF populations in various human cancers and helped to define key CAF subtypes, such as myofibroblastic, inflammatory, and antigen-presenting CAFs, with the first two being present in virtually all tumors. Importantly, these three CAF populations are involved in and modulate the positive and negative con-sequences of TAI. The remarkable plasticity of CAFs allows them to shift phenotypically and functionally in response to environ-mental changes. In this review, we describe how CAFs nurture tumor-promoting inflammation and suppress adaptive immu-nity. We also summarize the recently emerging evidence per-taining to tumor-suppressive CAF functions in the context of TAI. Finally, we summarize therapeutic concepts that aim at modulating CAF functions or depleting immunosuppressive CAFs to synergize with immunotherapy.

Details

einblenden:
ausblenden:
Sprache(n):
 Datum: 2023-03-142023-03-15
 Publikationsstatus: Erschienen
 Seiten: -
 Ort, Verlag, Ausgabe: -
 Inhaltsverzeichnis: -
 Art der Begutachtung: -
 Identifikatoren: ISI: 000972494200001
DOI: 10.1158/1078-0432.CCR-22-1031
PMID: 36399325
 Art des Abschluß: -

Veranstaltung

einblenden:

Entscheidung

einblenden:

Projektinformation

einblenden:

Quelle 1

einblenden:
ausblenden:
Titel: CLINICAL CANCER RESEARCH
Genre der Quelle: Zeitschrift
 Urheber:
Affiliations:
Ort, Verlag, Ausgabe: -
Seiten: - Band / Heft: 29 (6) Artikelnummer: - Start- / Endseite: 1009 - 1016 Identifikator: ISSN: 1078-0432